Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences (Nasdaq: SLDB) will participate in two investor conferences in late 2025 with senior management presenting in fireside chats.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Solid Biosciences (Nasdaq: SLDB) will participate in two investor conferences in late 2025 with senior management presenting in fireside chats.
- Jefferies Global Healthcare Conference (London) — Bo Cumbo, President and CEO, and Gabriel Brooks, MD, Chief Medical Officer, will speak on Nov 18, 2025 at 11:00 a.m. GMT (6:00 a.m. ET).
- Piper Sandler 37th Annual Healthcare Conference — the same executives will speak on Dec 2, 2025 at 11:30 a.m. ET.
Live webcasts will be available on the company Investors Events page, and replay files will be archived there for 30 days. Institutional investors seeking one-on-one meetings should contact their Jefferies or Piper Sandler representatives.
Details
News Market Reaction – SLDB
On Nov 11, the day this news came out, SLDB closed 9.16% above the previous close.
Data tracked by StockTitan Argus for the Nov 11 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHARLESTOWN, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:
- Jefferies Global Healthcare Conference in London
Bo Cumbo, President and CEO, and Gabriel Brooks, MD, Chief Medical Officer, will participate in a fireside chat on Tuesday, November 18, 2025, at 11:00 a.m. GMT (6:00 a.m. ET).
- Piper Sandler 37th Annual Healthcare Conference
Mr. Cumbo and Dr. Brooks will participate in a fireside chat on Tuesday, December 2, 2025, at 11:30 a.m. ET.
Live webcasts of the Jefferies and Piper Sandler fireside chats will be available on the Events page of the Investors section of the Company website or by clicking here. Webcast replays will be archived for 30 days on the Events page.
Institutional investors interested in one-on-one meetings with management during the conferences may reach out to their Jefferies or Piper Sandler representatives.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.